- Home
- PFO vs KPTI Comparison
PFO vs KPTI Comparison
Compare PFO & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFO | KPTI |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.3M | 172.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | PFO | KPTI |
|---|---|---|
| Price | $9.17 | $7.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 30.0K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $8.01 | $3.65 |
| 52 Week High | $9.90 | $10.99 |
Technical Indicators
Market Signals| Indicator | PFO | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 51.44 |
| Support Level | $8.85 | $5.53 |
| Resistance Level | $9.33 | $7.81 |
| Average True Range (ATR) | 0.12 | 0.78 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 76.34 | 52.72 |
Price Performance
Historical ComparisonAbout PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).